Abstract: An oseltamivir analog and nanoparticles having the analog bound thereto, of the present invention, strongly bind to oseltamivir-resistant influenza virus, and thus, the use of the same can allow detection of oseltamivir-resistant influenza viruses quickly and conveniently with the naked eye. Therefore, the present invention can be favorably utilized in promptly establishing a therapeutic schedule for a patient infected with influenza viruses.

Abstract: Provided herein are novel indoleacrylic acid-based compounds, and pharmaceutically acceptable salts thereof, useful for the production, maintenance and proliferation of pluripotent stem cells. Also provided are cell culture compositions comprising these compounds, and methods of using these compounds in the production and maintenance of pluripotent stem cells.

Abstract: The present invention relates to a method for producing a Polyporus squamosus-derived PSL1b recombinant lectin, which binds specifically to sialic acid containing glycoconjugates, from an Escherichia coli PSL1b strain (deposit number: KCTC12507BP) or a Pichia pastoris PSL1b strain (deposit number: KCTC12500BP) and a lectin produced thereby. The recombinant lectin of the present invention can be useful as an active ingredient of a composition or a kit for measuring or detecting glycoproteins, glycopeptides, glycolipids, sugar precursors, or oligosaccharides having sialic acid moieties.

Abstract: A near-infrared fluorescent probe for detecting ALP is represented by Chemical 1. The fluorescent probe capable of detecting ALP can selectively detect ALP only quickly and accurately. In addition, the fluorescent probe allows monitoring of a biological phenomenon occurring in cells and tissues through noninvasive in-vivo imaging and during the early osteogenic differentiation in real time.

Abstract: The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.

Abstract: The present invention relates to a method for preparing induced dopaminergic neuronal progenitors (iDPs) comprising inducing an expression of Oct4, Sox2, Klf4, and c-Myc genes in adult cells and direct reprogramming of the adult cells to the iDPs by treating the cells with sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8); and a cell therapy product and a composition for treating or preventing Parkinson's Disease (PD) which comprises the iDPs as active ingredients. In addition to this, the present invention relates to a method for preparing midbrain dopaminergic neurons comprising isolating NSC-like colony by culturing the iDPs, dissociating the isolated NSC-like colony, and culturing the cells on the neural cell differentiation medium. Further, the present invention relates to a method for treating PD or a method for screening medicine for preventing or treating PD using the cells of the present invention.

Abstract: The present invention relates to a versatile influenza virus vaccine composition using the HA2 helical domain of a hemagglutinin protein, which is an influenza surface protein, and to a pharmaceutical composition for preventing or treating influenza virus infectious diseases. The polypeptide expressed by SEQ ID NO: 3 and the polypeptide expressed by residues 379 to 474 of SEQ ID NO: 1 of the present invention can be mass-produced in E. coli, and effectively produce neutralizing antibodies to various influenza virus subtypes, and thus the polypeptides can be widely utilized as versatile vaccines for influenza virus subtypes and new influenza virus variants.

Abstract: The present invention relates to a fermented vegetable oil, to a method for preparing the oil, and to a composition including the oil. More particularly, the present invention relates to a technique for providing a fermented vegetable oil having the effects of enhancing emulsion stability due to water retention ability, improving texture and flavor, and enhancing moisturization.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to a screening method for a drug target gene by using chemical-genetic profile compendium of the heterozygous deletion fission yeast strain and the comparative genetic analysis using the same. More precisely, the present inventors constructed the chemical-genetic profile compendium for drug candidates from the heterozygous deletion fission yeast strain of Schizosaccharomyces pombe (S. pombe), and then compared with the compendium with the chemical-genetic profile compendium of the budding yeast Saccharomyces cerevisiae (S. cerevisiae) in order to select efficiently drug target genes showing drug sensitivity. The screening method of the present invention can be efficiently used for the identification of a drug target gene in various eukaryotes because it facilitates the selection of a drug target gene showing sensitivity to the drug from the chemical-genetic profile compendium of the heterozygous deletion fission yeast strain.

Abstract: The present invention relates to: a composition comprising a Sicyos angulatus extract or a fraction thereof as an effective ingredient for preventing, alleviating, or treating liver diseases; and a method for preventing or treating liver diseases, comprising a step of administering the composition to a subject suspected of having a liver disease.

Abstract: A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-? and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Abstract: The present invention concerns lectins isolated from the fruiting body of a novel Hericium erinaceum (deposit number: KCTC 12499BP) NEU-1L strain which bind specifically to sialic acid. The invention further pertains to uses of such lectinsn abd to processes for their preparation thereby. The lectin of the present invention can be useful as an active ingredient of a composition or a kit for measuring or detecting glycoproteins, glycopeptides, glycolipids, sugar precursors or oligosaccharides containing sialic acid moieties, or further for measuring or detecting cell lines, bacteria and viruses containing sialoglycoconjugates.

Abstract: The present invention relates to a method for producing medium chain diol and, more particularly to recombinant microorganisms in which fatty alcohol dehydrogenase and/or fatty alcohol oxidase genes on a ?-oxidative metabolism pathway are deleted, the fatty aldehyde dehydrogenase genes are optionally deleted, and ?-oxidative metabolism pathway-related genes are deleted, and to a method for producing medium chain diol from fatty acid-derived alcohol or alkane by culturing the recombinant microorganisms. The recombinant microorganisms of the present invention can produce a high yield of medium chain diol by preventing further oxidation and ?-oxidative metabolism of fatty alcohols.

Abstract: The present invention relates to a complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof, and relates to a pharmaceutical composition for preventing or treating an influenza virus infection comprising the complex as an active ingredient. Also, the present invention relates to a food composition for preventing or improving an influenza virus infection, a virucidal quasi-drug composition, a virucidal feed additive, and a feed, which comprises the complex as an active ingredient.

Abstract: The present invention relates to a method for producing a medium chain aminocarboxylic acid and, more particularly, to a recombinant microorganism in which a fatty aldehyde dehydrogenase gene in ?-oxidative metabolic pathway and a ?-oxidative metabolic pathway-related gene are deleted and a ?-transaminase gene is introduced, and a method for producing a medium chain aminocarboxylic acid by culturing the recombinant microorganism. The recombinant microorganism of the present invention can prevent additional oxidation of fatty aldehyde and ?-oxidative metabolism and also produce a medium chain aminocarboxylic acid, such as 12-aminodecane, as a raw material of nylon 12 from a substrate such as fatty acid with a high yield by introducing an amine group into a terminal thereof.

Abstract: The present invention relates to a method for producing a medium chain diamine and, more specifically, to a method for producing a medium chain diamine from an alcohol or alkane derived from a fatty acid, by culturing a recombinant microorganism from which a fatty aldehyde dehydrogenase gene in a ?-oxidative metabolic pathway and a ?-oxidative metabolic pathway related gene have been deleted, and also into which a ?-transaminase gene has been introduced. The recombinant microorganism disclosed in the present invention can prevent the additional oxidation and ?-oxidation metabolism of fatty aldehyde and can produce a medium chain diamine with a high yield by introducing an amine group to the terminus thereof.

Abstract: The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.

Abstract: The present invention relates to a method for preparing a recombinant microorganism simultaneously comprising genes encoding enzymes used in the biosynthesis pathway of 6-aminocaproic acid, which is a precursor of caprolactam, biosynthesizing 6-aminocaproic acid from the microorganism, and producing the same so as to synthesize caprolactam.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.